Indivior high after opioid drug's trial success

18 August 2016

Indivior (LSE: INDV) saw its share price rocket by 20% to £361.80 on Wednesday morning after announcing positive top-line Phase III results for its new opiod addiction drug.

The UK-based company is investigating the use of RBP-6000 buprenorphine monthly depot for the treatment of opioid use disorder, to be taken as part of a complete treatment plan including counseling and psychosocial support.

Indivior has told investors that it remains on track to complete the data analysis of its Phase III trial as well as the open-label long-term assessment of the safety and tolerability of RBP-6000, by the first quarter of 2017, in line with previous guidance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK